# Tolerability and Acceptance of Two Oral Hydrocortisone Compounding Formulation for Pediatrics

> **NCT06435481** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Hospital Universitari Vall d'Hebron Research Institute** · enrollment: 35 (estimated)

## Conditions studied

- Adrenal Insufficiency

## Interventions

- **DRUG:** 3D printed chewable formulation of hydrocortisone
- **DRUG:** Oral suspension of hydrocortisone

## Key facts

- **NCT ID:** NCT06435481
- **Lead sponsor:** Hospital Universitari Vall d'Hebron Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09
- **Primary completion:** 2025-09
- **Final completion:** 2026-09
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2024-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06435481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06435481, "Tolerability and Acceptance of Two Oral Hydrocortisone Compounding Formulation for Pediatrics". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06435481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*